Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3451
John B. Sanfilippo & Son
JBSS
$1.01B
| $917K | ﹤0.01% |
12,988
+1,876
| +17% | +$127K |
|
3452
Richtech Robotics
RR
$385M
| $916K | ﹤0.01% |
283,688
+184,774
| +187% | +$817K |
|
3453
Shenandoah Telecom
SHEN
$741M
| $916K | ﹤0.01% |
79,220
+7,290
| +10% | +$86.2K |
|
|
RZLV
3454
Rezolve AI
RZLV
$1.07B
| $912K | ﹤0.01% |
354,837
+108,038
| +44% | +$408K |
|
3455
Eagle Bancorp Montana
EBMT
$190M
| $911K | ﹤0.01% |
45,772
+1,980
| +5% | +$34.4K |
|
|
SKYT
3456
DELISTED
SkyWater Technology
SKYT
| $908K | ﹤0.01% |
50,002
+12,402
| +33% | +$215K |
|
3457
BlackSky Technology
BKSY
$1.27B
| $907K | ﹤0.01% |
48,399
+3,741
| +8% | +$76.3K |
|
3458
Redwire
RDW
$3.36B
| $906K | ﹤0.01% |
119,202
-251,635
| -68% | -$1.85M |
|
|
UDMY
3459
DELISTED
Udemy
UDMY
| $905K | ﹤0.01% |
154,766
-17,143
| -10% | -$100K |
|
3460
Vitesse Energy
VTS
$677M
| $905K | ﹤0.01% |
46,983
+3,475
| +8% | +$74.2K |
|
3461
CALL
UiPath
PATH
$8.12B
| $905K | ﹤0.01% |
+55,200
| New | +$859K |
|
3462
Republic Bancorp
RBCAA
$1.93B
| $900K | ﹤0.01% |
13,044
+1,246
| +11% | +$86.3K |
|
|
EFXT
3463
Enerflex
EFXT
$2.63B
| $898K | ﹤0.01% |
58,211
+42,771
| +277% | +$569K |
|
3464
Zevra Therapeutics
ZVRA
$668M
| $897K | ﹤0.01% |
100,135
-232,308
| -70% | -$2.2M |
|
3465
Hackett Group
HCKT
$275M
| $897K | ﹤0.01% |
45,706
+3,436
| +8% | +$65.2K |
|
3466
Aehr Test Systems
AEHR
$4.17B
| $896K | ﹤0.01% |
44,380
+4,160
| +10% | +$101K |
|
|
RPC
3467
Ridgepost Capital
RPC
$979M
| $895K | ﹤0.01% |
91,233
-86,040
| -49% | -$872K |
|
3468
The RMR Group
RMR
$343M
| $894K | ﹤0.01% |
59,989
+2,296
| +4% | +$35K |
|
3469
Orion Group Holdings
ORN
$397M
| $894K | ﹤0.01% |
89,908
+888
| +1% | +$8.61K |
|
3470
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$628M
| $893K | ﹤0.01% |
+5,600
| New | +$769K |
|
3471
MGP Ingredients
MGPI
$393M
| $891K | ﹤0.01% |
36,658
+5,674
| +18% | +$138K |
|
|
AHL
3472
DELISTED
Aspen Insurance
AHL
| $890K | ﹤0.01% |
23,999
+2,283
| +11% | +$84.2K |
|
|
VOYG
3473
Voyager Technologies
VOYG
$2.67B
| $890K | ﹤0.01% |
34,050
+14,706
| +76% | +$399K |
|
3474
Seneca Foods Class A
SENEA
$1.31B
| $889K | ﹤0.01% |
8,038
+1,477
| +23% | +$169K |
|
3475
PUT
Corcept Therapeutics
CORT
$12B
| $887K | ﹤0.01% |
25,500
-71,400
| -74% | -$5.61M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.